Skip to search formSkip to main contentSkip to account menu

lubiprostone

Known as: 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid, Lubiprostone [Chemical/Ingredient], Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11alpha)- 
A bicyclic fatty acid derived from prostaglandin E1 and a chloride channel activator with laxative activity. Upon intake, lubiprostone specifically… 
National Institutes of Health

Related topics

Related topics

13 relations

Broader (2)

AmitizaChloride Channel Agonists
In Bloodagonistsanalogs & derivativesantagonists & inhibitors

Narrower (2)

RU 0211SPI 0211

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype
Abstract Objectives Real-world patient outcomes data is scarce concerning the high disease burden of IBS-C. The aim of this study… 
Review
2014
Review
2014
Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome
The recent FDA provisional endpoint incorporates a one‐tailed measure of improvement for IBS based on the underlying motility… 
Review
2014
Review
2014
Treatment of abdominal pain in irritable bowel syndrome
Functional abdominal pain in the context of irritable bowel syndrome (IBS) is a challenging problem for primary care physicians… 
2013
2013
Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia.
Multiple sodium and chloride channels on the apical surface of nasal epithelial cells contribute to periciliary fluid homeostasis… 
Review
2013
Review
2013
Opioid Induced Bowel Disease: a Twenty-first Century Physicians’ Dilemma
The treatment of cancer-associated pain as well as chronic non-cancer-related pain (CNCP) is an increasingly relevant topic in… 
Review
2013
Review
2013
Novel therapies for constipation.
Constipation is a common medical problem and when standard laxatives fail it can be difficult to treat. Different aetiologies… 
2010
2010
Use of the Chloride Channel Activator Lubiprostone for Constipation in Adults with Cystic Fibrosis: A Case Series
Objective: To describe the use of lubiprostone for constipation in 3 adults with cystic fibrosis (CF). Case Summary: This case… 
Highly Cited
2009
Highly Cited
2009
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects.
Lubiprostone, a bicyclic fatty acid chloride channel activator, is efficacious in treatment of chronic constipation and… 
2009
2009
Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon.
Actions of lubiprostone, a selective type-2 chloride channel activator, on mucosal secretion were investigated in guinea pig… 
Review
2006
Review
2006
Defecation disorders: Neuromuscular aspects and treatment
Chronic constipation and fecal incontinence affect 20% of the population and are more prevalent in women, the elderly, those of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)